ZINC-BASED DIAGNOSTIC FOR PROSTATE CANCER

基于锌的前列腺癌诊断

• 批准号: 6486502
• 负责人: CHRISTOPHER J. FREDERICKSON
• 金额: $ 16.82万
• 依托单位: NEUROBIOTEX, INC.
• 依托单位国家: 美国
• 财政年份: 2002
• 资助国家: 美国
• 起止时间: 2002-09-01 至 2004-08-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6486502
• 关键词: clinical chemistry; clinical research; diagnosis design /evaluation; human tissue; male; method development; neoplasm /cancer diagnosis; prostate neoplasms; semen; zinc

DESCRIPTION(provided by applicant): We shall develop analytical tools for measuring the amount and speciation of zinc in semen; these tools will facilitate basic research and may lead to a zinc-based diagnostic kit for prostate cancer. According to the prevailing literature, semen zinc falls by 50 percent-90 percent in the early stages of prostate cancer while not changing in benign hypertrophy. If this is true, a combined measurement of semen zinc (falling in cancer) and serum PSA (rising in cancer) could provide sensitive and selective early diagnosis for prostate cancer. We envision test kits for routine testing of seminal zinc in the clinic, or even at home. Our Phase I goals are (i) develop methods and materials for measuring all the different seminal zinc pools (free, microligand-bound, protein bound, spermatozoan), (ii) establish preliminary norms for the various zinc pools in control men and (iii) measure the same parameters in samples from select prostate cancer patients. If Phase I results warrant continuation, in Phase II we will (i) prototype procedures for home/office kits for testing semen zinc, (ii) gather large-sample clinical data on zinc as a screening tool for prostate cancer (iii) develop quantitative models of the best multi-zinc pool diagnostic of cancer. PROPOSED COMMERCIAL APPLICATION: Commercial Potential: Yearly PSA testing is recommended for all men over 50, yet 40,000 men still die annually in the US alone from prostate cancer. If a zinc-based test were used along with PSA testing, the sales of the tests could be vast, and the contribution to men's health and wellness, equally vast.

描述（由申请人提供）：我们将开发分析工具， 测量精液中锌的数量和形态;这些工具将 促进基础研究，并可能导致锌基诊断试剂盒， 前列腺癌 根据流行的文献，精液锌福尔斯下降50%-90 前列腺癌的早期阶段的百分比，而良性前列腺癌的 肥厚如果这是真的，精液锌的联合测量（下降到 血清PSA（在癌症中升高）可以提供敏感和选择性的 前列腺癌的早期诊断我们设想用于常规检测的检测试剂盒 精液中的锌含量 我们的第一阶段目标是：（一）开发测量所有 不同的精液锌库（游离的，微配体结合的，蛋白结合的， 精子），（ii）建立各种锌库的初步规范 对照组和（iii）测量来自选择的样品中的相同参数 前列腺癌患者。 如果第一阶段的结果值得继续，在第二阶段，我们将（i）原型 家庭/办公室试剂盒测试精液锌的程序，（ii）收集 锌作为前列腺癌筛查工具的大样本临床数据 (iii)开发最佳多锌池诊断的定量模型， 癌 拟定商业应用： 商业潜力：每年PSA检测被推荐给所有50岁以上的男性，但仅在美国每年仍有4万名男性死于前列腺癌。如果锌基测试与PSA测试一起沿着使用，测试的销售可能是巨大的，对男性健康和健康的贡献也同样巨大。